Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.

By Aimee Look

Novartis said it is launching a direct-to-patient platform in the U.S. to sell a discounted version of its Cosentyx drug, the latest big pharma company to move to cut prices ahead of the Trump administration's deadline.

The Swiss pharmaceutical company said Monday that it would offer select units of Cosentyx--a drug treating immune-mediated inflammatory conditions like psoriasis and psoriatic arthritis--at a 55% discount to cash-paying patients with a prescription. The platform will come into effect on Nov. 1.

Novartis's launch of a direct-to-patient platform and the discount comes after President Trump said in a letter to pharmaceutical companies in July setting a deadline of Sept. 29 to impose cuts on drug prices.

AstraZeneca said last week that it would put up to a 70% discount on its asthma and diabetes drugs in the U.S. Bristol Myers Squibb said in the summer it would discount its plaque psoriasis drug at up to an 80% discount and expand discounts on its blood clot drug Eliquis.

Write to Aimee Look at [e-mail]

(END) Dow Jones Newswires

09-29-25 0859ET